Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP1 in Resectable Cutaneous SCC
NCT05858229Phase 2Active, not recruiting
- Start
- Jun 2023
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of vusolimogene oderparepvec in squamous cell carcinoma (SCC). Started Jun 2023; status: active, not recruiting.
02
Drugs
vusolimogene oderparepvec
03
Conditions
squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT05858229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05858229.